Jessica Hergert

Jennifer Marie Suga, MD, discusses the importance of understanding the current limitations to next-generation sequencing in oncology, the impact of the study findings, and remaining challenges regarding NGS testing in the community setting.

Sander Bach, discusses the rationale for conducting this systematic review in CRC, key inclusion/exclusion criteria, and the potential clinical implications of these findings.

Tanios S. Bekaii-Saab, MD, FACP, discusses the growing role of targeted therapy in CRC.

Lajos Pusztai, MD, DPhil, discusses the results from the I-SPY 2 trial, as well as the clinical implications of the findings.

Ivy P. Altomare, MD, the prognosis of patients with immune thrombocythemia, available treatment options, and emerging treatment modalities on the horizon.

Sandra Cuellar, PharmD, BCOP, discusses the benefits of using biosimilars in oncology, the approval process for these agents, and the reasons why biosimilars have been met with reluctance in the medical community.

Mario Sznol, MD, discusses the current immunotherapy paradigm in melanoma and promising agents that are in development.

External beam radiotherapy plus androgen deprivation therapy showed superior overall survival compared with EBRT plus a brachytherapy boost in men with intermediate- and high-risk prostate cancer.

Mario Sznol, MD, discusses the current immunotherapy paradigm in melanoma and promising agents that are in development.

Brian M. Slomovitz, MD, explaines the need to determine optimal sequencing strategies in endometrial cancer.

The first-in-class, synthetic hepcidin mimetic agent PTG-300 is being investigated in an ongoing phase 2 clinical trial, with the goal of introducing a novel therapeutic agent to the limited armamentarium in polycythemia vera.

Rushang D. Patel, MD, PhD, discusses the potential role of ruxolitinib in the treatment of patients with cGVHD.

Rushang D. Patel, MD, PhD, discusses the potential role of ruxolitinib in the treatment of patients with cGVHD. 

Hope S. Rugo, MD, discusses the research that was born from the results of the IMpassion130 trial and the future of immunotherapy in triple-negative breast cancer.

Hope S. Rugo, MD, discusses the research that was born from the results of the IMpassion130 trial and the future of immunotherapy in triple-negative breast cancer.

Combining the PD-1 inhibitor pembrolizumab with intratumoral plasmid interkeukin-12 electroporation elicited clinical responses in patients with immunologically quiescent advanced melanoma.

Combining the PD-1 inhibitor pembrolizumab with intratumoral plasmid interkeukin-12 electroporation elicited clinical responses in patients with immunologically quiescent advanced melanoma.

Toni K. Choueiri, MD, discusses the findings from the phase 1/2 trial, the clinical implications of targeting HIF-2α in kidney cancer, and the potential utility of MK-6482 in clear cell RCC.

Toni K. Choueiri, MD, discusses the findings from the phase 1/2 trial, the clinical implications of targeting HIF-2α in kidney cancer, and the potential utility of MK-6482 in clear cell RCC. 

Adam M. Brufsky, MD, PhD, discusses the impact of the COVID-19 pandemic on patients with cancer, as well as the science behind the proposed explanation of the immunopathology of COVID-19.

Neehar Parikh, MD, sheds light on the role of multidisciplinary care in hepatocellular carcinoma, other therapeutic modalities on the horizon, and anticipated sequencing challenges in the paradigm.

Neehar Parikh, MD, sheds light on the role of multidisciplinary care in HCC, other therapeutic modalities on the horizon, and anticipated sequencing challenges in the paradigm. 

Riad Salem, MD, discusses the role of localized therapy in hepatocellular carcinoma, the need to personalize treatment for patients, and the importance of implementing a multidisciplinary approach in this setting.

Sonali M. Smith, MD, sheds light on some of the recent advances in follicular lymphoma and mantle cell lymphoma, as well as the challenges that remain overall in non-Hodgkin lymphoma.

Ritu Salani, MD, discusses the evolving role of biomarker development and testing in cervical cancer.

FGFR2 fusions are significantly less common in endemic fluke-associated cholangiocarcinoma compared with non–fluke-associated cholangiocarcinoma, demonstrating that distinct etiologies could affect the molecular landscape of cholangiocarcinoma tumors.

Udai Banerji, discusses the rationale for a phase 1 trial, the potential implications of these data, and future studies in development.

Scott T. Tagawa, MD, MS, FACP, provides background on radionuclide therapy, sheds light on the key findings from the trial, and discusses future directions with 225Ac-J591 in mCRPC.

Lloyd B. Gayle, MD, discusses the current treatment of patients with breast implant–associated ALCL and remaining questions that need to be addressed.

Kevin Hughes, MD, highlights the need for widespread implementation of genetic testing in breast cancer.